• Upstream Bio presented new Phase 2 VIBRANT trial data at the ATS 2026 International Conference on verekitug in adults with chronic rhinosinusitis with nasal polyps, including patients with comorbid asthma.
• The analyses showed improved asthma symptom control in patients with comorbid asthma, alongside consistent reductions in nasal polyp burden and sinonasal symptoms versus placebo.
• Verekitug also lowered the need for rescue systemic steroids or sinus surgery in the comorbid asthma subgroup.
• A separate post hoc analysis indicated rapid, sustained reductions in type 2 inflammatory biomarkers in blood and nasal secretions, supporting the drug’s proposed mechanism in airway inflammation.
• Upstream Bio expects to start dosing Phase 3 registrational trials in CRSwNP and severe asthma in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181130PRIMZONEFULLFEED9722168) on May 18, 2026, and is solely responsible for the information contained therein.